Skip to main content

Advertisement

Log in

Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The use of monoclonal antibody, rituximab, had been reported to be associated with some severe viral infections. The inference of rituximab therapy and post-transplant cytomegalovirus (CMV) infectious complications in non-Hodgkin’s lymphoma (NHL) patients is still unclear now. From 2002 to 2005, 46 patients with relapsed indolent or high-risk aggressive B cell NHL who received rituximab (17 patients) or not (29 patients) before autologous hematological stem cell transplantation (HSCT) in one institute were retrospectively analyzed for the risk factors of CMV complications after transplantation. Pre-transplant and post-transplant CMV infectious conditions, conditioning regimens, transplant types, and post-transplant complications were recorded. Post-transplant infectious complications were followed up until 6 months after transplantation.Seventeen of 46 patients received rituximab before HSCT. Three of them suffered from CMV infection and two of them developed CMV disease. All of the patients with CMV disease recovered after ganciclovir and CMV-specific immunoglobulin therapy. Twenty-nine of 46 patients without rituximab treatment before HSCT did not have CMV complications after HSCT. The risks to develop CMV infections after autologous HSCT were higher in rituximab-treated patients (17.6% vs 0%, p = 0.045, Fisher exact test, two-sided). The risks to develop CMV diseases had higher trend with rituximab therapy than without rituximab therapy (11.7% vs 0%, p = 0.131, Fisher exact test, two-sided). The NHL patients receiving rituximab therapy had higher risk to develop CMV infectious complications after autologous HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P et al (1987) Prolonged disease-free survival after autologous bone marrow transplantation in patient with non-Hodgkin’s lymphoma with a poor prognosis. N Engl J Med 316:1499–1505

    Article  PubMed  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545

    Article  PubMed  CAS  Google Scholar 

  3. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC et al (1996) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780–2786

    PubMed  CAS  Google Scholar 

  4. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325–3333

    PubMed  CAS  Google Scholar 

  5. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L et al (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694–704

    Article  PubMed  CAS  Google Scholar 

  6. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al (2005) Immunochemotherapy with Rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984–1992

    Article  PubMed  CAS  Google Scholar 

  7. Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T (2003) Safety and feasibility of CHOP/Rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin’s lymphoma. Bone Marrow Transplant 31:775–782

    Article  PubMed  CAS  Google Scholar 

  8. Brugger W, Hirsch J, Graunebach F, Repp R, Brossart P, Vogel W et al (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15:1691–1698

    Article  PubMed  CAS  Google Scholar 

  9. Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I et al (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin’s lymphoma. Br J Haematol 122:457–464

    Article  PubMed  CAS  Google Scholar 

  10. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V et al (2004) Effects of pretransplantation treatment with Rituximab on outcomes autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 22:4561–4566

    Article  PubMed  CAS  Google Scholar 

  11. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation Rituximab. Blood 99:1486–1488

    Article  PubMed  CAS  Google Scholar 

  12. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM (2002) Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100:1104–1105

    Article  PubMed  Google Scholar 

  13. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following Rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894–895

    PubMed  CAS  Google Scholar 

  14. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of Rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000

    Article  PubMed  CAS  Google Scholar 

  15. Vallet S, Tempescul A, Tran A, Legrand-Quillien MC, Narbonne V, Berthou C (2005) Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and Rituximab. Ann Hematol 84:545–547

    Article  PubMed  CAS  Google Scholar 

  16. Rossini F, Terruzzi E, Cammarota S, Morini F, Fumagalli M, Verga L et al (2005) Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis 7:122–125

    Article  PubMed  CAS  Google Scholar 

  17. Damaj G, Charbonnier A, Bouabdallah R, Vey N, Coso D, Stoppa AM et al (2004) Monoclonal antibodies and cytomegalovirus infections. Eur J Haematol 73:73–74

    Article  PubMed  CAS  Google Scholar 

  18. Bai LY, Chiou TJ, Liu JH, Yen CC, Wang WS, Yang MH et al (2004) Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan. Ann Hematol 83:38–43

    Article  PubMed  CAS  Google Scholar 

  19. Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ (2005) Clincal and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79:381–386

    Article  PubMed  Google Scholar 

  20. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094–1097

    Article  PubMed  Google Scholar 

  21. de la Hoz RE, Stephens G, Sherlock C (2002) Diagnosis and treatment approaches of CMV infections in adult patients. J Clin Virol suppl 2:S1–S12

    Google Scholar 

  22. Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J et al (2001) Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 39(11):3938–3941

    Article  PubMed  CAS  Google Scholar 

  23. Derzko-Dzulynsky LA, Berger AR, Berinstein NL (1998) Cytomegalovirus retinitis and low-grade non-Hodgkin’s lymphoma: case report and review of the literature. Am J Hematol 57:228–232

    Article  PubMed  CAS  Google Scholar 

  24. Fassas AB, Bolanos-Meade J, Buddharaaju LN, Rapoport A, Cottler-Fox M, Chen T et al (2001) Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 112:237–241

    Article  PubMed  CAS  Google Scholar 

  25. Lee KC, Chang CY, Chuang YC, Young MS, Huang CM, Yin WH et al (2004) Heart transplant coronary artery disease in Chinese recipients. Transplant Proc 36:2380–2383

    Article  PubMed  CAS  Google Scholar 

  26. Vieira CA, Agarwal A, Book BK, Sindner RA, Bearden CM, Gebel HM et al (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77:542–548

    Article  PubMed  CAS  Google Scholar 

  27. Nakai K, Kanda Y, Mineishi S, Satio T, Ohnishi M, Niiya H et al (2002) Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 29:237–241

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study got the grant support from Taiwan Clinical Cancer Research Foundation and Taipei Veterans General Hospital (VGH-92–255).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tzeon-Jye Chiou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, MY., Chiou, TJ., Hsiao, LT. et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 87, 285–289 (2008). https://doi.org/10.1007/s00277-007-0397-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-007-0397-0

Keywords

Navigation